We first performed an integrated pan-cancer analysis of GYS2 in GEPIA database, and found that GYS2 was significantly down-regulated in a variety of tumors, especially in hepatobiliary tumors. This evidence concerns the gene GYS2 and hepatobiliary neoplasm.